The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | TOPAZ-1: 3-year survival, eLTS & safety of durvalumab and chemotherapy in BTC
Do-Youn Oh, MD, PhD, Seoul National University College of Medicine, Seoul, South Korea, discusses the updated 3-year survival, extended long-term survival (eLTS), and safety results from the Phase III TOPAZ-1 study (NCT03875235) in advanced biliary tract cancer (BTC). The study compared durvalumab with gemcitabine and cisplatin against placebo with gemcitabine and cisplatin . After a median follow-up of 41.3 months significant long-term survival benefits with manageable safety were observed in patients receiving durvalumab. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
